PDCD1 and neoplasm: While additional studies are warranted to evaluate the effects of L-DOS47 administration on immune cell subsets in the tumor microenvironment, it is nonetheless clear that the combination of L-DOS47 with anti-PD1 remained the most effective treatment overall in this study.